EPA and HHS Launch Initiative to Monitor Microplastics and Pharmaceuticals in Drinking Water

The U.S. Environmental Protection Agency and Department of Health and Human Services will monitor microplastics and pharmaceuticals in drinking water to assess health risks. This move adds the contaminants to the sixth Contaminant Candidate List, supporting new policies under the Safe Drinking Water Act to protect public health from emerging threats.

The U.S. Environmental Protection Agency (EPA) and the Department of Health and Human Services (HHS) have announced their initiative to monitor microplastics and pharmaceuticals in drinking water. This joint effort marks a milestone in evaluating potential health risks and crafting new policies to safeguard the public.

The inclusion of these contaminants in the sixth Contaminant Candidate List initiates rigorous testing and monitoring under the Safe Drinking Water Act. EPA Administrator Lee Zeldin emphasized that understanding and measuring these elements is crucial to future regulation and protecting water systems.

This move has faced criticism from MAHA activists who argue that concerns over microplastics have been long overlooked. However, supporters view this as a pivotal step toward addressing pressing environmental health issues and aligning with President Donald Trump's agenda focused on national health priorities.